<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-1146</journal-id>
<journal-title><![CDATA[Boletín médico del Hospital Infantil de México]]></journal-title>
<abbrev-journal-title><![CDATA[Bol. Med. Hosp. Infant. Mex.]]></abbrev-journal-title>
<issn>1665-1146</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud, Hospital Infantil de México Federico Gómez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-11462017000300219</article-id>
<article-id pub-id-type="doi">10.1016/j.bmhimx.2017.03.003</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Omics-based biomarkers: current status and potential use in the clinic]]></article-title>
<article-title xml:lang="es"><![CDATA[Biomarcadores basados en tecnologías ómicas: estado actual y su potencial uso en la clínica]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Quezada]]></surname>
<given-names><![CDATA[Héctor]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guzmán-Ortiz]]></surname>
<given-names><![CDATA[Ana Laura]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Díaz-Sánchez]]></surname>
<given-names><![CDATA[Hugo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Valle-Rios]]></surname>
<given-names><![CDATA[Ricardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguirre-Hernández]]></surname>
<given-names><![CDATA[Jesús]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez Laboratorio de Investigación en Inmunología y Proteómica ]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Politécnico Nacional Escuela Nacional de Ciencias Biológicas Departamento de Microbiología]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Uiversidad Nacional Autónoma de México Facultad de Medicina División de Investigación]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital Infantil de México Federico Gómez Genética y Bioinformática Laboratorio de Genómica]]></institution>
<addr-line><![CDATA[ Mexico City]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2017</year>
</pub-date>
<volume>74</volume>
<numero>3</numero>
<fpage>219</fpage>
<lpage>226</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-11462017000300219&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-11462017000300219&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-11462017000300219&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract: In recent years, the use of high-throughput omics technologies has led to the rapid discovery of many candidate biomarkers. However, few of them have made the transition to the clinic. In this review, the promise of omics technologies to contribute to the process of biomarker development is described. An overview of the current state in this area is presented with examples of genomics, proteomics, transcriptomics, metabolomics and microbiomics biomarkers in the field of oncology, along with some proposed strategies to accelerate their validation and translation to improve the care of patients with neoplasms. The inherent complexity underlying neoplasms combined with the requirement of developing well-designed biomarker discovery processes based on omics technologies present a challenge for the effective development of biomarkers that may be useful in guiding therapies, addressing disease risks, and predicting clinical outcomes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen: En los últimos años, el uso de las tecnologías ómicas de alta densidad de datos ha permitido el rápido descubrimiento de posibles biomarcadores. Sin embargo, esto no ha tenido un impacto notable en la clínica ya que se han implementado muy pocos de esos biomarcadores. En el presente documento se describe el potencial de las tecnologías ómicas en el desarrollo de nuevos biomarcadores. Con el objetivo de dar a conocer un panorama general de la situación actual, se comentan algunos ejemplos ilustrativos de biomarcadores genómicos, transcriptómicos, proteómicos, metabolómicos y microbiómicos en el campo de la investigación en oncología. Asimismo, se señalan algunas de las recomendaciones que se han propuesto para acelerar su validación e implementación, y se comenta sobre cómo la complejidad inherente a las enfermedades se combina con la complejidad de las tecnologías ómicas, de tal modo que el desarrollo de biomarcadores predictivos, pronósticos y diagnósticos eficientes plantea retos importantes.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Biomarker]]></kwd>
<kwd lng="en"><![CDATA[Genomics]]></kwd>
<kwd lng="en"><![CDATA[Proteomics]]></kwd>
<kwd lng="en"><![CDATA[Metabolomics]]></kwd>
<kwd lng="es"><![CDATA[Biomarcador]]></kwd>
<kwd lng="es"><![CDATA[Genómica]]></kwd>
<kwd lng="es"><![CDATA[Proteómica]]></kwd>
<kwd lng="es"><![CDATA[Metabolómica]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A new initiative on precision medicine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Collins]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Varmus]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2015</year>
<volume>372</volume>
<page-range>793-5</page-range></nlm-citation>
</ref>
<ref id="B2">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Delivering precision medicine in oncology today and in future&#8212;the promise and challenges of personalised cancer medicine: a position paper by the European Society for Medical Oncology (ESMO)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ciardiello]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Arnold]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Casali]]></surname>
<given-names><![CDATA[PG]]></given-names>
</name>
<name>
<surname><![CDATA[Cervantes]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Douillard]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Eggermont]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Ann Oncol]]></source>
<year>2014</year>
<volume>25</volume>
<page-range>1673-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Biomarker development in the precision medicine era: lung cancer as a case study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargas]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Harris]]></surname>
<given-names><![CDATA[CC]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2016</year>
<volume>16</volume>
<page-range>525-37</page-range></nlm-citation>
</ref>
<ref id="B4">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Implementing personalized cancer genomics in clinical trials]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Roychowdhury]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Drug Discov]]></source>
<year>2013</year>
<volume>12</volume>
<page-range>358-69</page-range></nlm-citation>
</ref>
<ref id="B5">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Identity by descent and candidate gene mapping of Richieri-Costa and Pereira syndrome]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ferreira de Lima]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Moretti-Ferreira]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Richieri-Costa]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Murray]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Med Genet A]]></source>
<year>2003</year>
<volume>122A</volume>
<page-range>56-8</page-range></nlm-citation>
</ref>
<ref id="B6">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The prognostic ease and difficulty of invasive breast carcinoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tofigh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Suderman]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Paquet]]></surname>
<given-names><![CDATA[ER]]></given-names>
</name>
<name>
<surname><![CDATA[Livingstone]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bertos]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Saleh]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell Rep]]></source>
<year>2014</year>
<volume>9</volume>
<page-range>129-42</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McShane]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Polley]]></surname>
<given-names><![CDATA[MY]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Trials (London)]]></source>
<year>2013</year>
<volume>10</volume>
<page-range>653-65</page-range></nlm-citation>
</ref>
<ref id="B8">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Sensitivity, specificity, PPV, and NPV for predictive biomarkers]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2015</year>
<page-range>107</page-range></nlm-citation>
</ref>
<ref id="B9">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genomic biomarkers in predictive medicine. An interim analysis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[EMBO Mol Med]]></source>
<year>2011</year>
<volume>3</volume>
<page-range>429-35</page-range></nlm-citation>
</ref>
<ref id="B10">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Biomarker based clinical trial design]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simon]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Chin Clin Oncol]]></source>
<year>2014</year>
<volume>3</volume>
<page-range>39</page-range></nlm-citation>
</ref>
<ref id="B11">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Silencing and overexpression of human blood group antigens in transfusion: paving the way for the next steps]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bagnis]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood Rev]]></source>
<year>2015</year>
<volume>29</volume>
<page-range>163-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Expanded newborn screening by mass spectrometry: new tests, future perspectives]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ombrone]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Giocaliere]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Forni]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Malvagia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[la Marca]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<source><![CDATA[Mass Spectrom Rev]]></source>
<year>2016</year>
<volume>35</volume>
<page-range>71-84</page-range></nlm-citation>
</ref>
<ref id="B13">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Prostate cancer biomarkers: are we hitting the mark?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McGrath]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Christidis]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Perera]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hong]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Manning]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Vela]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<source><![CDATA[Prostate Int]]></source>
<year>2016</year>
<volume>4</volume>
<page-range>130-5</page-range></nlm-citation>
</ref>
<ref id="B14">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that over-expresses HER2]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Slamon]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Leyland-Jones]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Shak]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Fuchs]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Paton]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Bajamonde]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2001</year>
<volume>344</volume>
<page-range>783-92</page-range></nlm-citation>
</ref>
<ref id="B15">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Current status of ABL tyrosine kinase inhibitors stop studies for chronic myeloid leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kimura]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Stem Cell Investig]]></source>
<year>2016</year>
<volume>3</volume>
<page-range>36</page-range></nlm-citation>
</ref>
<ref id="B16">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Minor histocompatibility antigens: past, present, and future]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Spierings]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<source><![CDATA[Tissue Antigens]]></source>
<year>2014</year>
<volume>84</volume>
<page-range>347-60</page-range></nlm-citation>
</ref>
<ref id="B17">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Where are all the new omics-based tests?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bossuyt]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Chem]]></source>
<year>2014</year>
<volume>60</volume>
<page-range>1256-7</page-range></nlm-citation>
</ref>
<ref id="B18">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Analytical validation of the Oncotype DX genomic diagnostic test for recurrence prognosis and therapeutic response prediction in node-negative, estrogen receptor-positive breast cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cronin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Sangli]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Pho]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dutta]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Chem]]></source>
<year>2007</year>
<volume>53</volume>
<page-range>1084-91</page-range></nlm-citation>
</ref>
<ref id="B19">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prat]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Parker]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Perou]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
</person-group>
<source><![CDATA[Breast Cancer Res Treat]]></source>
<year>2012</year>
<volume>135</volume>
<page-range>301-6</page-range></nlm-citation>
</ref>
<ref id="B20">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A gene-expression signature as a predictor of survival in breast cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van de Vijver]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[YD]]></given-names>
</name>
<name>
<surname><![CDATA[van&#8217;t Veer]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
<name>
<surname><![CDATA[Dai]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Hart]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[Voskuil]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2002</year>
<volume>347</volume>
<page-range>1999-2009</page-range></nlm-citation>
</ref>
<ref id="B21">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnostic associations of gene expression signatures in prostate cancer tissue]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nguyen]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Welty]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cooperberg]]></surname>
<given-names><![CDATA[MR]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Urol]]></source>
<year>2015</year>
<volume>25</volume>
<page-range>65-70</page-range></nlm-citation>
</ref>
<ref id="B22">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Oncotype DX(®) colon cancer assay for prediction of recurrence risk in patients with stage II and III colon cancer: a review of the evidence]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[You]]></surname>
<given-names><![CDATA[YN]]></given-names>
</name>
<name>
<surname><![CDATA[Rustin]]></surname>
<given-names><![CDATA[RB]]></given-names>
</name>
<name>
<surname><![CDATA[Sullivan]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<source><![CDATA[Surg Oncol]]></source>
<year>2015</year>
<volume>24</volume>
<page-range>61-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A genomic and clinical prognostic index for hepatitis C-related early-stage cirrhosis that predicts clinical deterioration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[King]]></surname>
<given-names><![CDATA[LY]]></given-names>
</name>
<name>
<surname><![CDATA[Canasto-Chibuque]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Johnson]]></surname>
<given-names><![CDATA[KB]]></given-names>
</name>
<name>
<surname><![CDATA[Yip]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Kojima]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Gut]]></source>
<year>2015</year>
<volume>64</volume>
<page-range>1296-302</page-range></nlm-citation>
</ref>
<ref id="B24">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Multitarget stool DNA testing for colorectal-cancer screening]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Imperiale]]></surname>
<given-names><![CDATA[TF]]></given-names>
</name>
<name>
<surname><![CDATA[Ransohoff]]></surname>
<given-names><![CDATA[DF]]></given-names>
</name>
<name>
<surname><![CDATA[Itzkowitz]]></surname>
<given-names><![CDATA[SH]]></given-names>
</name>
<name>
<surname><![CDATA[Levin]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Lavin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Lidgard]]></surname>
<given-names><![CDATA[GP]]></given-names>
</name>
</person-group>
<source><![CDATA[N Engl J Med]]></source>
<year>2014</year>
<volume>370</volume>
<page-range>1287-97</page-range></nlm-citation>
</ref>
<ref id="B25">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Cancer biomarker discovery and validation]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goossens]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Nakagawa]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Sun]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Hoshida]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Transl Cancer Res]]></source>
<year>2015</year>
<volume>4</volume>
<page-range>256-69</page-range></nlm-citation>
</ref>
<ref id="B26">
<nlm-citation citation-type="book">
<article-title xml:lang=""><![CDATA[Committee on the Review of Omics-Based Tests for Predicting Patient Outcomes in Clinical Trials; Board on Health Care Services; Board on Health Sciences Policy; Institute of Medicine]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Micheel]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[Nass]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Omenn]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
</person-group>
<source><![CDATA[Evolution of translational omics: lessons learned and the path forward]]></source>
<year>2012</year>
<publisher-loc><![CDATA[Washington (DC) ]]></publisher-loc>
<publisher-name><![CDATA[National Academies Press]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B27">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A comprehensive multicenter comparison of whole genome sequencing pipelines using a uniform tumor-normal sample pair]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Buchhalter]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Hutter]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Alioto]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Boutros]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Brors]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<source><![CDATA[bioRxiv]]></source>
<year>2014</year>
</nlm-citation>
</ref>
<ref id="B28">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Proteomic methods for biomarker discovery and validation. Are we there yet?]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hathout]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[Expert Rev Proteomics]]></source>
<year>2015</year>
<volume>12</volume>
<page-range>329-31</page-range></nlm-citation>
</ref>
<ref id="B29">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The path to routine use of genomic biomarkers in the cancer clinic]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Boutros]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<source><![CDATA[Genome Res]]></source>
<year>2015</year>
<volume>25</volume>
<page-range>1508-13</page-range></nlm-citation>
</ref>
<ref id="B30">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Five years of GWAS discovery]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Visscher]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[MI]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Hum Genet]]></source>
<year>2012</year>
<volume>90</volume>
<page-range>7-24</page-range></nlm-citation>
</ref>
<ref id="B31">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A systematic review of cancer GWAS and candidate gene meta-analyses reveals limited overlap but similar effect sizes]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[CQ]]></given-names>
</name>
<name>
<surname><![CDATA[Yesupriya]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rowell]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Pimentel]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Clyne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gwinn]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Eur J Hum Genet]]></source>
<year>2014</year>
<volume>22</volume>
<page-range>402-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Vocal cord and pharyngeal weakness with auto-somal dominant distal myopathy: clinical description and gene localization to 5q31]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Feit]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Silbergleit]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Schneider]]></surname>
<given-names><![CDATA[LB]]></given-names>
</name>
<name>
<surname><![CDATA[Gutierrez]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Fitoussi]]></surname>
<given-names><![CDATA[RP]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Hum Genet]]></source>
<year>1998</year>
<volume>63</volume>
<page-range>1732-42</page-range></nlm-citation>
</ref>
<ref id="B33">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Reversibility of oncogene-induced cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Felsher]]></surname>
<given-names><![CDATA[DW]]></given-names>
</name>
</person-group>
<source><![CDATA[Curr Opin Genet Dev]]></source>
<year>2004</year>
<volume>14</volume>
<page-range>37-42</page-range></nlm-citation>
</ref>
<ref id="B34">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[AP-1: a double-edged sword in tumorigenesis]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eferl]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Wagner]]></surname>
<given-names><![CDATA[EF]]></given-names>
</name>
</person-group>
<source><![CDATA[Nat Rev Cancer]]></source>
<year>2003</year>
<volume>3</volume>
<page-range>859-68</page-range></nlm-citation>
</ref>
<ref id="B35">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Population isolates: their special value for locating genes for bipolar disorder]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Escamilla]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
</person-group>
<source><![CDATA[Bipolar Disord]]></source>
<year>2001</year>
<volume>3</volume>
<page-range>299-317</page-range></nlm-citation>
</ref>
<ref id="B36">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genome wide scan using homozygosity mapping and linkage analyses of a single pedigree with affective disorder suggests oligogenic inheritance]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ewald]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Kruse]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Mors]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
</person-group>
<source><![CDATA[Am J Med Genet B Neuropsychiatr Genet]]></source>
<year>2003</year>
<volume>120B</volume>
<page-range>63-71</page-range></nlm-citation>
</ref>
<ref id="B37">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The current use and attitudes towards tumor genome sequencing in breast cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gingras]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sonnenblick]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[de Azambuja]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Paesmans]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Delaloge]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aftimos]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Sci Rep]]></source>
<year>2016</year>
<volume>6</volume>
<page-range>22517</page-range></nlm-citation>
</ref>
<ref id="B38">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The biology of relapsed acute lymphoblastic leukemia: opportunities for therapeutic interventions]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhatla]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
<name>
<surname><![CDATA[Meyer]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Vitanza]]></surname>
<given-names><![CDATA[NA]]></given-names>
</name>
<name>
<surname><![CDATA[Raetz]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
</person-group>
<source><![CDATA[J Pediatr Hematol Oncol]]></source>
<year>2014</year>
<volume>36</volume>
<page-range>413-8</page-range></nlm-citation>
</ref>
<ref id="B39">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Molecular biomarkers in acute myeloid leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Prada-Arismendy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Arroyave]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Röthlisberger]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood Rev]]></source>
<year>2017</year>
<volume>31</volume>
<page-range>63-76</page-range></nlm-citation>
</ref>
<ref id="B40">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Drug resistance in cancer: an overview]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Housman]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Byler]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Heerboth]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Lapinska]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Longacre]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Snyder]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Cancers (Basel)]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>1769-92</page-range></nlm-citation>
</ref>
<ref id="B41">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children&#8217;s Oncology Group study]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhojwani]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kang]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Moskowitz]]></surname>
<given-names><![CDATA[NP]]></given-names>
</name>
<name>
<surname><![CDATA[Min]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Potter]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2006</year>
<volume>108</volume>
<page-range>711-7</page-range></nlm-citation>
</ref>
<ref id="B42">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[The gene expression signature of relapse in paediatric acute lymphoblastic leukaemia: implications for mechanisms of therapy failure]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beesley]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[Cummings]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Firth]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ford]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Haematol]]></source>
<year>2005</year>
<volume>131</volume>
<page-range>447-56</page-range></nlm-citation>
</ref>
<ref id="B43">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Epigenetic reprogramming reverses the relapse-specific gene expression signature and restores chemosensitivity in childhood B-lymphoblastic leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bhatla]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Morrison]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Raetz]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
<name>
<surname><![CDATA[Burke]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Brown]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>119</volume>
<page-range>5201-10</page-range></nlm-citation>
</ref>
<ref id="B44">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genome-wide copy number profiling reveals molecular evolution from diagnosis to relapse in childhood acute lymphoblastic leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Bhojwani]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Cai]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Stocco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Crews]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2008</year>
<volume>112</volume>
<page-range>4178-83</page-range></nlm-citation>
</ref>
<ref id="B45">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mullighan]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Goorha]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Radtke]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Coustan-Smith]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Dalton]]></surname>
<given-names><![CDATA[JD]]></given-names>
</name>
</person-group>
<source><![CDATA[Nature]]></source>
<year>2007</year>
<volume>446</volume>
<page-range>758-64</page-range></nlm-citation>
</ref>
<ref id="B46">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Fan]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<source><![CDATA[JAMA]]></source>
<year>2009</year>
<volume>301</volume>
<page-range>393-403</page-range></nlm-citation>
</ref>
<ref id="B47">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Cheng]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Devidas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cao]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Campana]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<source><![CDATA[Blood]]></source>
<year>2012</year>
<volume>120</volume>
<page-range>4197-204</page-range></nlm-citation>
</ref>
<ref id="B48">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[A panel of glycoproteins as candidate biomarkers for early diagnosis and treatment evaluation of B-cell acute lymphoblastic leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cavalcante]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Torres-Romero]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Lobo]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Moreno]]></surname>
<given-names><![CDATA[FB]]></given-names>
</name>
<name>
<surname><![CDATA[Bezerra]]></surname>
<given-names><![CDATA[LP]]></given-names>
</name>
<name>
<surname><![CDATA[Lima]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
</person-group>
<source><![CDATA[Biomark Res]]></source>
<year>2016</year>
<volume>4</volume>
<page-range>1</page-range></nlm-citation>
</ref>
<ref id="B49">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Identification of prognostic protein biomarkers in childhood acute lymphoblastic leukemia (ALL)]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kham]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Koh]]></surname>
<given-names><![CDATA[GS]]></given-names>
</name>
<name>
<surname><![CDATA[Suang Lim]]></surname>
<given-names><![CDATA[JY]]></given-names>
</name>
<name>
<surname><![CDATA[Ariffin]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Chew]]></surname>
<given-names><![CDATA[FT]]></given-names>
</name>
</person-group>
<source><![CDATA[J Proteomics]]></source>
<year>2011</year>
<volume>74</volume>
<page-range>843-57</page-range></nlm-citation>
</ref>
<ref id="B50">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Quantitative proteomic analysis reveals maturation as a mechanism underlying glucocorticoid resistance in B lineage ALL and re-sensitization by JNK inhibition]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nicholson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Evans]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Matheson]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Minto]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Keilty]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sanichar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Br J Haematol]]></source>
<year>2015</year>
<volume>171</volume>
<page-range>595-605</page-range></nlm-citation>
</ref>
<ref id="B51">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Label-free quantitative proteomics reveals differentially expressed proteins in high risk childhood acute lymphoblastic leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chi]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Gu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Proteomics]]></source>
<year>2017</year>
<volume>150</volume>
<page-range>1-8</page-range></nlm-citation>
</ref>
<ref id="B52">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Identification of potential predictive markers of dexamethasone resistance in childhood acute lymphoblastic leukemia]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dehghan-Nayeri]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Rezaei-Tavirani]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Omrani]]></surname>
<given-names><![CDATA[MD]]></given-names>
</name>
<name>
<surname><![CDATA[Gharehbaghian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Goudarzi Pour]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Eshghi]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<source><![CDATA[J Cell Commun Signal]]></source>
<year>2016</year>
</nlm-citation>
</ref>
<ref id="B53">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Detection of circulating tumor DNA in early- and late-stage human malignancies]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bettegowda]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sausen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Leary]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kinde]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Agrawal]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<source><![CDATA[Sci Transl Med]]></source>
<year>2014</year>
<volume>6</volume>
<page-range>224ra24</page-range></nlm-citation>
</ref>
<ref id="B54">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Miolo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Muraro]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Caruso]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Crivellari]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Ash]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Scalone]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncotarget]]></source>
<year>2016</year>
<volume>7</volume>
<page-range>39809-22</page-range></nlm-citation>
</ref>
<ref id="B55">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Diagnosis of bladder cancer and prediction of survival by urinary metabolomics]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jin]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Yun]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jeong]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[IY]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncotarget]]></source>
<year>2014</year>
<volume>5</volume>
<page-range>1635-45</page-range></nlm-citation>
</ref>
<ref id="B56">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Verification of the biomarker candidates for non-small-cell lung cancer using a targeted proteomics approach]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sertamo]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Pierrard]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Mesmin]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[SY]]></given-names>
</name>
<name>
<surname><![CDATA[Schlesser]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[J Proteome Res]]></source>
<year>2015</year>
<volume>14</volume>
<page-range>1412-9</page-range></nlm-citation>
</ref>
<ref id="B57">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Genomic analysis identifies association of Fusobacterium with colorectal carcinoma]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kostic]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Gevers]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Pedamallu]]></surname>
<given-names><![CDATA[CS]]></given-names>
</name>
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Duke]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Earl]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<source><![CDATA[Genome Res]]></source>
<year>2012</year>
<volume>22</volume>
<page-range>292-8</page-range></nlm-citation>
</ref>
<ref id="B58">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kostic]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
<name>
<surname><![CDATA[Chun]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Robertson]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Glickman]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Gallini]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Michaud]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Cell Host Microbe]]></source>
<year>2013</year>
<volume>14</volume>
<page-range>207-15</page-range></nlm-citation>
</ref>
<ref id="B59">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Current state of circulating microRNAs as cancer biomarkers]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Kong]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Huang]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[TK]]></given-names>
</name>
</person-group>
<source><![CDATA[Clin Chem]]></source>
<year>2015</year>
<volume>61</volume>
<page-range>1138-55</page-range></nlm-citation>
</ref>
<ref id="B60">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[MicroRNA-143 is a putative predictive factor for the response to fluoropyrimidine-based chemotherapy in patients with metastatic colorectal cancer]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[Simmer]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Venderbosch]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Dijkstra]]></surname>
<given-names><![CDATA[JR]]></given-names>
</name>
<name>
<surname><![CDATA[Vink-Börger]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Faber]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mekenkamp]]></surname>
<given-names><![CDATA[LJ]]></given-names>
</name>
</person-group>
<source><![CDATA[Oncotarget]]></source>
<year>2015</year>
<volume>6</volume>
<page-range>22996-3007</page-range></nlm-citation>
</ref>
<ref id="B61">
<nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration]]></article-title>
<person-group person-group-type="author">
<name>
<surname><![CDATA[McShane]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Cavenagh]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Lively]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Eberhard]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Bigbee]]></surname>
<given-names><![CDATA[WL]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<source><![CDATA[BMC Med]]></source>
<year>2013</year>
<volume>11</volume>
<page-range>220</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
